Semax and neuroinflammation research: what evidence shows

Semax and neuroinflammation research mainly covers animal studies of brain blood-flow loss. These studies measured gene activity and selected proteins, not a proven direct calming effect on brain inflammation.

Key takeaways

• Semax is a short, synthetic peptide based on part of a pituitary hormone.
• Most detailed findings come from animal models of brain blood-flow loss.
• Results change with the model, brain region, and time of sampling.
• Changes in RNA do not prove changes in proteins or brain function.
• Human studies have not established a direct effect on brain inflammation.

What Semax is and how researchers study it

Semax is a synthetic peptide, meaning a short chain of amino acids made in a set order. It is based on part of ACTH, a hormone made by the pituitary gland.

Its seven amino acids come from a changed ACTH fragment. The sequence is also written as ACTH(4-7)PGP.

Peptide makers join amino acids in a chosen order. Enzymes can break these chains down, so the amount of time they remain in a body can vary by route and species.

Researchers have not confirmed one receptor that explains Semax's reported brain effects. Suggested pathways are ideas for testing, not proof that Semax acts directly on a specific receptor.

These limits matter when reading Semax studies of brain inflammation. A finding in one species or model cannot by itself establish the same effect in people.

Why ischemia models and timing matter

Cerebral ischemia means that blood flow to the brain falls. Reperfusion means blood flow returns, and that return can also affect brain tissue.

Temporary blockage models include both reduced flow and its return. In one rat model, researchers blocked the right middle cerebral artery with a thin thread for 90 minutes, as reported in Genes.

Permanent blockage models leave the artery blocked during the study. A rat gene study used permanent middle cerebral artery occlusion, and its results come from a different model than temporary blockage and reperfusion.

Model details shape what a result can mean. Tissue from one brain area, sampled at one time, may differ from another area or time point.

For this reason, comparisons should name the type of blockage, the brain region, and the time of sampling. A result from a permanent model does not settle what happens during temporary ischemia and reperfusion.

What gene studies found after ischemia

Gene expression means how much RNA a cell makes from a gene. RNA sequencing reads RNA in a sample, while a microarray checks RNA against a set of selected probes.

A transcriptome is the set of RNA messages found in a sample. These methods can show which gene messages rise or fall, but they do not directly measure working proteins.

The largest number of genes (96) showed altered expression after Semax, three hours after ischemia began, using a 1.50 cut-off, according to BMC Genomics.

Semax altered expression in 68 genes 24 hours after occlusion; expression rose in 51, according to BMC Genomics.

Only 10 genes overlapped at the two time points, and their responses to Semax were contradictory, according to BMC Genomics. That split shows why one sampling time cannot describe the whole response.

RNA changes alone do not show that protein levels changed, that cells behaved differently, or that brain function improved. A gene shift in injured tissue also does not prove that Semax reversed the injury.

To separate treatment-related changes from injury-related changes, studies need suitable comparison groups. They also need to measure outcomes beyond RNA when testing claims about cell activity or brain function.

How inflammatory and vascular signals fit in

Neuroinflammation is the brain's immune response. Cytokines are proteins that carry immune signals, while chemokines help guide immune cells.

In a rat study after temporary artery blockage, researchers measured several protein markers at 24 hours. The published review reported higher active CREB in subcortical structures, lower MMP-9 and c-Fos in nearby frontoparietal cortex, and lower active JNK in both areas.

CREB is a protein that helps control gene activity. MMP-9 is an enzyme linked to tissue change, c-Fos is a marker of cell response, and JNK is a stress-signalling protein.

These measured changes do not prove that Semax reduced brain inflammation. Immune-related or blood-vessel-related gene changes can point to questions for later tests, but they do not settle what happened to the immune response.

Brain tissue samples can contain many cell types. Without cell-specific tests, findings from mixed tissue cannot show whether Semax acted directly on microglia, the brain's resident immune cells, or on astrocytes, support cells in the brain.

A rat study measured Semax-linked protein changes 24 h after middle cerebral artery blockage.

From molecular signals to brain function

Semax altered expression in 24 vascular-system genes three hours after permanent middle cerebral artery blockage and 12 genes 24 hours after blockage, according to BMC Genomics.

Researchers also discuss brain-derived neurotrophic factor (BDNF), a protein that supports nerve-cell survival and connections. Neurotransmission, the process by which nerve cells signal each other, is another area linked to proposed brain effects.

These signals may help researchers choose what to test next. They do not prove neuroprotection, meaning less damage to nerve cells, unless studies also measure cell damage or brain function.

A link between gene changes and a neurological outcome does not show that one caused the other. Studies need to measure both and test whether the proposed link holds across models.

Stroke models cannot establish benefits for healthy thinking, dementia, or long-term prevention. Those claims require studies designed to measure those outcomes directly.

What human evidence can and cannot tell us

Animal studies provide most of the detailed gene-expression findings on Semax and ischemia. They do not establish that the same changes happen in people.

Some human studies have examined Semax in stroke settings. They do not establish that Semax directly reduces brain inflammation or acts on a specific brain cell type.

A direct test would measure inflammation-related proteins or cell actions alongside brain function and clinical outcomes. That design could show whether a molecular change appears with a meaningful change in function.

Readers should judge each result by its model, tissue, sampling time, and measured outcome. A proposed mechanism alone cannot establish a clinical effect.

Conclusion

Semax and neuroinflammation research offers animal findings on gene activity and selected protein markers after brain ischemia. The results vary by model, tissue, and sampling time, and they do not prove a direct anti-inflammatory action or a human benefit.